Gilead Extends Tender Offer for Arcellx
Gilead has extended its tender offer to acquire Arcellx until April 24, 2026. The offer remains $115 per share in cash plus a CVR.
IQVIA: German pharma market up in value in 2025, volumes slightly down
IQVIA reports 5.7% sales growth in Germany’s pharma market in 2025, while volumes slipped by 0.7%. In pharmacies, Rx grew faster than OTC.
Gilead to acquire Ouro Medicines for clinical BCMAxCD3 program
Gilead Sciences plans to buy Ouro Medicines for up to $2.175bn, adding OM336, a clinical BCMAxCD3 T cell engager for autoimmune diseases.
Hims & Hers shifts US weight loss strategy with Novo Nordisk deal
Hims & Hers is refocusing its US weight loss business and teaming up with Novo Nordisk, prioritizing access to a wider set of FDA-approved GLP-1 drugs.
Sandoz launches azelastine/fluticasone nasal spray in Germany and Switzerland
Sandoz has launched an azelastine/fluticasone nasal spray in Germany and Switzerland, expanding access to a fixed-dose allergy treatment option.
Sandoz partners with Samsung Bioepis on up to five biosimilars
Sandoz and Samsung Bioepis agreed to collaborate on up to five biosimilar assets, starting with an early-stage vedolizumab biosimilar program.
BC Partners and Bpifrance complete acquisition of Biogaran
BC Partners and Bpifrance have completed the acquisition of Biogaran from Servier. Erick Roche is set to become CEO by the end of March 2026.
Hikma reports revenue and core profit growth, launches buyback and reshuffles leadership
Hikma posted 2025 revenue and core profit growth, lifted its dividend and announced a US$250m share buyback plus immediate leadership changes.
Esperion to acquire Corstasis to add Enbumyst to its CV portfolio
Esperion has signed a definitive deal to acquire Corstasis. The transaction adds Enbumyst, an FDA-approved bumetanide nasal spray for edema.
BioMarin withdraws hemophilia gene therapy Roctavian
BioMarin is withdrawing Roctavian from the market after divestiture efforts failed, booking about $240M in Q4 2025 charges tied to the exit.
Novo Nordisk to invest €432m in Athlone manufacturing site
Novo Nordisk will invest €432m in its Athlone, Ireland, tabletting plant to add manufacturing capacity for current and future oral GLP-1 therapies.
GSK agrees to acquire 35Pharma, adding pulmonary hypertension asset HS235
GSK has agreed to acquire Canada’s 35Pharma for $950m in cash, gaining HS235, an activin signalling inhibitor being developed for pulmonary hypertension.
Novo Nordisk partners with Vivtex on oral biologics
Novo Nordisk and Vivtex will work on oral biologics for obesity and diabetes. Vivtex is eligible for up to US$2.1 billion plus tiered royalties.
Merck reshapes business ahead of Keytruda patent expiry
Merck & Co. is splitting operations into two divisions to prepare for Keytruda’s 2030 patent expiry and to broaden its portfolio.
medac Group exits diagnostics business to focus on pharma
medac Group is divesting its diagnostics activities via a management buy-out to focus on pharma. The business will continue as mevida Diagnostika.
Hameln to host second nursing congress on the future of care
Sana Klinikum Hameln-Pyrmont will host the “Pflege bewegt” nursing congress on 16 April 2026 in Hameln, focusing on future nursing practice.
DMEA sparks Award 2026 opens call for digital health theses
DMEA has opened applications for the sparks Award 2026, honouring bachelor’s and master’s theses on healthcare digitalisation. Deadline: 31 January 2026.
WEFRA MEDIAPLUS GLOBAL HEALTH Sets New Standards in Healthcare Media
With WEFRA MEDIAPLUS GLOBAL HEALTH, Mediaplus Group and WEFRA LIFE GROUP combine their strengths to deliver scalable, international healthcare campaigns. The joint venture connects global strategies with strong local execution.
New care concept strengthens outpatient follow-up for cardiac patients
Novartis Germany and the Ambulatory Heart Center Kassel are launching a new outpatient care concept to support structured follow-up care for cardiac patients, with a focus on LDL cholesterol. The goal is to sustainably reduce risk factors through standardized treatment pathways.
Drug spending rises, pharmacy remuneration stagnates
Statutory health insurance drug spending rose as forecast in 2025. Pharmacy remuneration, however, continues to stagnate despite rising costs and declining prescription volumes.